- Zacks
Doximity (DOCS) Upgraded to Buy: Here's What You Should Know
Doximity (DOCS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Fortune
Exclusive: Doctors hit their breaking point as 86% fear for the future of American medicine: ‘We are often stretched quite thin’
Pay increased nearly 6% in 2023—not enough to account for inflation and low reimbursements, found Doximity.
